Neuphoria Therapeutics (NEUP) Income from Continuing Operations (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Income from Continuing Operations for 4 consecutive years, with -$505063.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 104.48% year-over-year to -$505063.0 in Q1 2026; TTM through Mar 2026 was -$23.7 million, a 346.04% decrease from a year earlier, with the FY2025 full-year figure at -$6.6 million, up 43.15% from the prior year.
• Income from Continuing Operations was -$505063.0 for Q1 2026 at Neuphoria Therapeutics, down from $1.9 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at $11.3 million in Q1 2025 and troughed at -$15.2 million in Q2 2025.
• A 4-year average of -$2.4 million and a median of -$1.9 million in 2024 frame the typical range for Income from Continuing Operations.
• The widest YoY moves for Income from Continuing Operations: up 505.38% in 2025, down 1452.68% in 2025.
• Over 4 years, Income from Continuing Operations stood at -$4.6 million in 2023, then jumped by 57.33% to -$1.9 million in 2024, then surged by 195.92% to $1.9 million in 2025, then tumbled by 127.09% to -$505063.0 in 2026.
• The last three Income from Continuing Operations figures came in at -$505063.0 (Q1 2026), $1.9 million (Q4 2025), and -$9.9 million (Q3 2025), per Business Quant data.